Low reproducibility across laboratories, differences in experimental platforms and techniques, the inherent heterogeneity of prostate cancer, and insignificant clinical utility or small gains in sensitivity and specificity beyond PSA hampers the identification, validation, and implementation of biomarkers [30–35]. Here, KLK3 is linked to prostate cancer.